Drug Trial Radar · NCT03050294
Evaluating Treatment Resistant Dermatitis TaroIIR
Last checked: Nov 20, 2026Latest source record: May 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 1, 2017
Primary completion
Jun 1, 2017
Study completion Jun 1, 2017
Sponsor
- Lead sponsor
- Wake Forest University Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 10, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.
Conditions
- Atopic Dermatitis
- Psoriasis
Interventions
Phone callsBehavioral
Phone calls twice daily
Desoximetasone 0.25% sprayDrug
Desoximetasone 0.25% spray applied twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Global Assessment- Atopic DermatitisTime frame: 1 week
- Investigator Global Assessment- PsoriasisTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.